Status
Conditions
Treatments
About
Study evaluating the activity and efficacy of Stereotactic Body Radiotherapy for the treatment of medically inoperable localized renal cancer
Full description
Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative to surgery to control localized primary renal cell cancer (RCC) in medically inoperable patients. The kidney tumor has classically been considered radioresistant. Multiple retrospective series and few Phase II trial have studied the role of SBRT in localized renal tumors with favorable outcomes. Although large prospective studies are lacking, we evaluate the safety and effectiveness of SBRT for the treatment of renal cancer.
Participants will be allocated to recieve either single 26Gy fraction or Multifraction 3 - 5 fraction-squeme.
Assesment at regular intervals will estimate the activity and efficacy of the technique, evaluate tolerability, estimate survival, estimate distant failure rate, and renal function change after SABR.
Follow-up visits occur at 1month and every 3 months in the first year after SBRT, then every 6 months in the second year and then yearly until study closure.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
60 participants in 1 patient group
Loading...
Central trial contact
Nicolás Feltes, MD; Manuel Galdeano-Rubio, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal